The prophylactic use of topical antiviral agents has recently been validated by the reduction in human immunodeficiency virus (HIV) type 1 infection incidence seen using tonofovir-containing microbicides. In order to develop a wide-spectrum microbicide to prevent infection with a wide range of sexually transmitted viruses, we have previously reported the development of HIVneutralizing aptamers and here report the isolation and characterization of aptamers that neutralize herpes simplex virus type 2 (HSV-2). These aptamers bind the envelope glycoprotein (gD), are potent (IC 50 of 20-50 nM) and are able to block infection pathways dependent on both major entry receptors, Nectin1 and HVEM. Structural analysis and mutagenesis of these aptamers reveal a core specificity element that could provide the basis for pharmaceutical development. As HSV-2 is a major risk factor for the acquisition of HIV-1, a microbicide capable of preventing HSV-2 infection would not only reduce the morbidity associated with HSV-2, but also that derived from HIV-1.
Aptamers are nucleic acid-based molecules capable of specifically binding a target molecule with high affinity (Bunka et al., 2010; James, 2001) . Their ability to fold into a variety of complex, sequence-specific tertiary conformations means that aptamers can bind a wide range of targets and rival antibodies in their potential diversity. Using the SELEX approach (Ellington & Szostak, 1990; Robertson & Joyce, 1990; Tuerk & Gold, 1990) , our groups have previously isolated aptamers capable of discriminating between wild-type and disease-associated prion protein conformations (Rhie et al., 2003) and between monomeric and amyloid fibrils of b2-microglobulin (Bunka et al., 2007) , and have generated a neutralizing aptamer against the gp120 envelope glycoprotein of human immunodeficiency virus (HIV) type 1 (Khati et al., 2003) , which is currently being developed for use as a microbicide against HIV-1 transmission (Moore et al., 2011) .
Herpes simplex virus type 2 (HSV-2) is a major risk factor in the acquisition of HIV-1 infection (Freeman et al., 2006) . Infection with HSV-2 has been estimated to enhance the likelihood of becoming HIV-1-positive by two-to threefold, irrespective of overt clinical disease symptoms (Renzi et al., 2003) . With worldwide HSV-2 prevalence of over 16 % (70 % in sub-Saharan African women) (Looker et al., 2008) , it is clear that prevention of HSV-2 transmission would have a major impact on reducing the frequency of HIV-1 infection. To this end, we set out to generate an HSV-2-neutralizing aptamer, with the goal of incorporating it into a multivalent microbicide approach to curb the HIV-1 pandemic and prevent the spread of HSV-2.
Entry of HSV-2 into its target cell involves an initial interaction between the viral envelope proteins, gB or gC, with heparan sulfate proteoglycans on the cell surface (Spear, 2004) . Subsequently, the viral gD protein binds to one of its receptors, Nectin1 or HVEM (Taylor et al., 2007) , thereby initiating cell entry through the co-operative fusogenic action of gD, gB and gH/gL proteins. The interaction between gD and its receptors is an essential, non-redundant stage during virus infection and, therefore, is an ideal target for neutralization using aptamers.
Using a robotic protocol for SELEX based on a previously described method (Bunka et al., 2007) , aptamers were selected from a degenerate library of~10 14 sequences by virtue of their binding to an immobilized gD-IgG fusion protein. Bound RNA was recovered at each round by thermal denaturation, reverse transcribed and amplified by PCR to give an enriched DNA pool. To provide stability to the aptamers in biological fluids, all RNAs were transcribed using 29-fluoro-pyrimidines incorporated using Y639F T7 RNA polymerase (Sousa & Padilla, 1995) . After 10 rounds of selection, the RNA pool was counter-selected against IgG to remove aptamers that had been selected on the basis of IgG binding. Subsequently, a single round of selection was performed as before, except that aptamers were eluted using competition with gD protein in solution, thereby ensuring high specificity of binding. In a final round of selection, the aptamer pool was passed over the gD-IgG fusion protein, immobilized on a BIAcore sensorchip and left under continuous buffer flow for 20 min to allow weakly associated species to be washed away. Aptamers which remained bound were eluted from the gD protein using washes of increasing ionic strength containing NaCl concentrations ranging from 100 mM to 1 M, and finally with 8 M urea (Fig. 1a) . These fractions were recovered and amplified as described previously (Fig. 1b) .
The aptamer pool from round 10 of selection and the pools eluted from the sensorchip by 1 M NaCl or 8 M urea were then tested for activity against HSV-2 (Fig. 1c) . Aptamer pools at a final concentration of 1 mM were co-incubated with HSV-2 strain 333 [diluted in complete medium (CM), i.e. Dulbecco's modified Eagle's medium (DMEM), 10 % (v/v) FCS, 1 % (v/v) penicillin/streptomycin, to provide roughly 100 plaques per well] for 1 h at 37 u C. Vero cells, which naturally express both HSV-2 entry receptors (Nectin1 and HVEM), plated the previous day at 2610 5 cells per well of a 12-well plate were then exposed to 200 ml aptamer/virus mix. At 2 h post-infection, cells were washed and then layered with a semi-solid medium [DMEM supplemented with 1 % (v/v) FCS and 1 % (w/v) carboxymethylcellulose] to limit cell-free virus spread. At 2 days post-infection, cells were fixed and stained [0.1 % (w/v) amido black, 6 % (v/v) acetic acid, 166 mM sodium acetate] to identify cytopathic plaques. Plaque numbers were counted and compared to those for virus alone (Neg) and the original pool of unselected aptamers (Naïve). The results show that all three aptamer pools post-selection for gD binding are able to neutralize HSV-2 to a similar extent to a gD-binding antibody (III-174.1, at 333 ng ml 21 ) (Para et al., 1985) .
The isolated aptamer pools were cloned into the pGEM-T Easy sequencing vector (Promega) and used to transform Escherichia coli; blue/white screening was used to identify colonies containing an aptamer insert. These were picked and individual aptamers were isolated by PCR using primers specific to regions flanking the vector multiple cloning site. The individual RNA aptamers were transcribed from the PCR product as before and a number of the clones were tested for activity against HSV-2. Due to the laborious nature of plaque screening, a high throughput assay was developed to screen the aptamer clones for activity using a modified replication-competent HSV-2 clone encoding the marker gene b-galactosidase, HSV-2(333)UL3/4Gal (Manoj et al., 2004) . For this assay, aptamer clones were mixed at a final concentration of 100 nM with virus diluted in CM to 2610 4 p.f.u. ml 21 for 1 h at 37 u C. Vero cells plated the previous day at 1610 4 cells per well of a 96-well plate were then exposed to 50 ml aptamer/virus mix for 2 h at 37 u C before adding 50 ml CM. At 16 h post-infection, cells were assayed for expression of b-galactosidase using a chemiluminescent reporter assay (Promega). Results for representative aptamers were then plotted relative to the infectivity of the virus without aptamer present and are comparable to those with the plaque assay (Fig. 1d) . A panel of aptamer clones was tested in Vero cells using the b-galactosidase assay and it was clear that some of the aptamers were able to neutralize HSV-2 (t-test, P,0.001) (Fig. 2a) . In contrast, the naïve pool of unselected aptamers, an aptamer derived against the HIV-1 gp120 protein (UCLA1; Khati et al., 2003) and a number of the gD-binding aptamer clones showed little to no inhibitory effects against HSV-2 when assayed in Vero cells.
In order to identify which receptor-binding site was mediating the effects of the aptamers, the neutralization assay was also performed in CHO cells exogenously induced to stably express human Nectin1 or HVEM (Geraghty et al., 1998; Montgomery et al., 1996) . The parental CHO cell line was also tested as it has been reported to express an endogenous receptor that can promote a low level of virus entry (Yoon et al., 2003) . For CHO-derived cell lines, the b-galactosidase assay was altered by plating twice the number of cells, replacing DMEM with F12 media, and by increasing the virus inoculum twofold for CHO-Nectin1 and CHO-HVEM cell lines and 10-fold for the parental CHO cell line to produce similar levels of infection compared to Vero cells. Inhibition of HSV-2 by the aptamer clones in CHO-Nectin1 cells was similar to that in the original Vero cell line (Fig. 2b) , suggesting that the aptamers predominantly interfere with gD-Nectin1 interactions. In contrast, many of the noninhibitory aptamers in both the Vero and CHO-Nectin1 cell lines showed some degree of antiviral activity in CHO-HVEM and CHO cells ( Fig. 2c and d, respectively) when compared to the 'no aptamer' control (Neg). The two aptamer controls, naïve and UCLA1, also showed apparent inhibition in these CHO-HVEM and CHO cells, implying that RNA aptamers are able to inhibit infection of HSV-2 using either HVEM or the endogenous CHO receptor in a non-specific manner (possibly through electrostatic interference). These results resemble previously published mutagenesis studies that have identified many gD mutations that prevent binding to both Nectin1 and HVEM or HVEM alone, but only a few that affect only Nectin1 binding (Spear et al., 2006) . It is worth noting that this 'non-specific' inhibition of HSV-2 is specific to the CHO-HVEM and CHO cell lines as they are identical to CHONectin1 (except for the single entry receptor transgene), in which this effect was not observed. Moreover, our aptamers appear to be highly selective for HSV-2 as they showed no neutralizing activity against HSV-1 in Vero cells (data not shown). These results contrast with neutralizing antibodies targeting the gD protein, which generally show cross-reactivity, inhibiting both viruses (Para et al., 1985) . Also, representative aptamers had no effect on the unrelated virus HIV-1 in TZM-bl cells (Derdeyn et al., 2000; Wei et al., 2002) , as measured by b-galactosidase expression (Fig. 2e) , when pseudotyped with either HIV-1 BaL envelope or vesicular stomatitis virus (VSV) protein G envelope glycoprotein.
The potency of selected clones was then addressed by performing serial dilutions of the aptamers and testing them against HSV-2 in Vero cells. Representative dilution series of the naïve aptamer pool, a non-functional clone (F11) and the active G7a clone are shown in Fig. 2(f) . The results show that the G7a clone is able to inhibit HSV-2 infection in Vero cells with an IC 50 of 20 nM, whereas the naïve pool and F11 clone are both non-functional in these cells. Other active anti-HSV-2 aptamers produced in this study gave IC 50 values ranging from 20 to 50 nM (data not shown).
The anti-HSV-2 aptamer clones were then sequenced to identify any conserved functional motifs. CLUSTAL W analysis of the unique sequences suggested a conserved motif, CTCGTTRACCCACTACGAGCG (underlined sequence showing the highest level of prevalence), present in most aptamers active in Vero and CHO-Nectin1 cells (Fig. 3a) . Following association to the chip-bound gD, dissociating aptamers were collected at 2 min intervals, after each NaCl wash and after the 8 M urea wash. The collected aptamers were amplified by RT-PCR and analysed by PAGE. A DNA size marker (M) is also shown. (c) Aptamer pools after either 10 rounds of SELEX (Round 10), washed from the BIAcore chip-bound gD (1 M NaCl) or eluted from the chip (8 M urea) were tested for neutralization of HSV-2 in a Vero cell plaque assay. Results were compared to the pool of unselected aptamers (Naïve) and a neutralizing anti-gD antibody at 333 ng ml "1 (anti-gD). Neg, Virus alone (no aptamer). Two independent experiments are shown, with lines indicating the mean (*P,0.001, one-way ANOVA with Bonferroni correction). (d) The level of HSV-2 infectivity, normalized to no aptamer control (Neg), is shown for two aptamer clones (D5 and C11 at 100 nM) and for the anti-gD antibody (2 mg ml "1 ) measured in both a plaque assay (circles, representing individual wells, with lines indicating the mean) and the b-galactosidase assay (bars, representing the mean±standard error of three independent experiments performed in duplicate).
HSV-2 neutralizing aptamers
Only one aptamer, D9, active in Vero and CHO-Nectin1 cells did not contain any sequence resembling this motif, which may indicate a secondary binding site on gD through which aptamers can affect its function. No motifs were identified within the sequenced aptamers active in only CHO and CHO-HVEM cells (data not shown). All results are normalized to the no aptamer control (Neg) and represent the mean±standard error of three independent experiments performed in duplicate (*P,0.001, one-way ANOVA with Bonferroni correction). (e) Infectivity of VSV-g and BaL-pseudotyped HIV-1 exposed to aptamers (100 nM) were determined in TZM-bl cells using the b-galactosidase assay (TZM-bl cells express b-galactosidase in response to HIV-1 infection). Results depict the mean±standard error of three independent experiments. (f) Serial dilutions of the naïve aptamer pool (#), an inactive clone (F11; h) and an active clone (G7a; g) were assayed for neutralization of HSV-2. The concentration at which 50 % of virus was neutralized (IC 50 , dotted line) was calculated by non-linear regression for aptamer G7a. Means±standard error of two independent experiments performed in triplicate are shown.
In order to probe its significance, the structure of the conserved motif within two different aptamers was investigated. The lowest energy structure predictions for both F2 and D5 were calculated using MFold (Mathews et al., 1999; Zuker, 2003) (Fig. 3b and c, respectively) . The accuracy of the predicted structures was confirmed by nuclease digestion of radiolabelled aptamers using the nucleases T1 (cleaves after single-stranded G residues), S1 (cleaves any single-stranded residue) and V1 (cleaves double-stranded or structurally constrained nucleotides) (cleavage sites identified by arrowheads on the MFold structure; Fig. 3b and c) . The structure of the F2 aptamer contains four stem-loops (I, II, III and IV) and the highly conserved central ACCCA sequence is found at the apex of loop II, whereas D5 has three stem-loops with ACCCA at the apex of stem-loop III. The presence of a confirmed stem-loop with an apical ACCCA motif on two very different aptamer sequences and its presence in the predicted structures of all aptamers active in Vero and CHO-Nectin1 cells suggest that the motif may be significant. To confirm a functional role of the ACCCA motif, three aptamers were designed based on the sequence of F2, D5 and G7a but with the ACCCA motif mutated to AAAAA (F2m, D5m and G7am, respectively). This alteration had no effect on their predicted secondary structures (MFold), but abolished the aptamers' anti-HSV-2 activity in both Vero and CHO-Nectin1 cells ( Fig.  3d and e, respectively) . The modified aptamers were also less effective than their parental sequences at inhibiting HSV-2 infection of CHO-HVEM and CHO cells, but notably some activity remained ( Fig. 3f and g, respectively) . These results confirm that: (i) the majority of entry in Vero cells is via the Nectin1 receptor; (ii) the ACCCA motif is required for these aptamers to prevent a functional interaction between gD and both Nectin1 and HVEM; and (iii) RNA aptamers are able to affect the functional interaction between gD and HVEM (and the endogenous receptor on CHO cells) in a sequenceindependent manner.
In this article, we have described the isolation of numerous RNA-based aptamers that bind to the gD protein of HSV-2. Infection of Vero cells, as well as CHO cells encoding HSV-2 receptors, is reduced in the presence of these antigD aptamers. Thus, we have identified a novel molecule capable of neutralizing HSV-2, one that we believe could be included in future microbicidal products to prevent transmission of sexually transmitted viruses. MFold secondary structure prediction of the full-length aptamers F2 and D5, respectively. The predicted structures are overlaid with cleavage sites identified by the nuclease digestion reactions (T1, white arrowheads; S1, black arrowheads; V1, grey arrowheads). The ACCCA motif at the apex of stem-loop II and III are also highlighted. (d) Vero, (e) CHO-Nectin1, (f) CHO-HVEM and (g) CHO cells were infected with HSV-2 in the presence of three aptamers (F2, D5 and G7a) and their mutated derivatives (F2m, D5m and G7am). Bars represent the mean±standard error of three independent experiments performed in duplicate, normalized to infectivity in the absence of aptamers (Neg).
